Haichuang Pharmaceutical announced that the company received a notice from the US Food and Drug Administration, and the clinical trial application for HP570 tablets independently developed by the company to treat rheumatoid arthritis was officially approved by the FDA.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.